Hematology

This therapeutic could work for diseases of the B cell receptor signaling transduction pathway that do not respond well to single-agent BTK inhibitor.

According to the findings, the use of venetoclax, as well as other new therapies, improved overall survival from 28.6% to 45.3% in non-Hispanic Black patients with AML.

The CAR T-cell therapy improved relative overall survival by more than a third compared to standard of care.

Expert discusses positive, real-world findings from a claims-based study looking at this therapeutic.

These drugs have interesting mechanisms, unique use, or may support expanded indications in the future.

Investigators will evaluate prophylactic tocilizumab prior to treatment with teclistamab.

Although treatment is effective, AEs remain difficult for patients.

There is progress being made regarding research on immunotherapies and the mutation, which adversely affects a higher number of patients in this population.

These data support the combination of daratumumab plus VRd followed by daratumumab and lenalidomide maintenance as a new standard of care for transplant-eligible patients.

Compared to placebo plus chemotherapy, quizartinib plus chemotherapy improved OS without significant AEs and impact on QOL in patients with AML.

In a recent study, people who lived in disadvantaged or rural areas were just as likely to receive the second-generation medications as people in urban areas.

However, a survival benefit was observed with using a signaling inhibitor in general for patients with angioimmunoblastic T-cell lymphoma.

The authors note that CAR-T cell therapy could change the treatment standard for patients with DLBCL, who previously had few options if standard chemotherapy treatment was ineffective.

The model may help clinicians identify patients who would benefit from disease-specific therapies or enrollment into clinical trials.

The pharmacist can help patients to manage symptoms throughout the entire treatment journey.

Expert breaks down these findings and more from the GLAMM1 study at the 2023 ASH Annual Meeting.

This is the first trial to show that a measurable residual disease (MRD)–guided approach with treatment beyond MRD negativity has a significant advantage over chemotherapy, both in terms of progression-free survival and overall survival.

The study results shine a light on the potential need for further policy changes that promote gender equity and bridge the gap in R01 funding awarded to female applicants.

Median overall survival is set to be more than 2 years, which is more than double the overall survival of current frontline therapies.

He also provides insight for students training in classical hematology, oncology hematology, or oncology pharmacy.

The efficacy of treatments, which is the outcomes in the ideal clinical trial setting, are known to often be better than the effectiveness of those treatments, which are the outcomes of patients in the real-world setting.

The study findings have implications for the identification of novel pathways with which to selectively target folate-metabolism blood cancers.

The president highlights a new curative treatment option for sickle cell disease while also expanding on the changing treatment landscape for hematologic conditions.

This FDA approval represents the first cell-based gene therapies for the treatment of sickle cell disease in patients 12 years of age and older.

ASH is happening December 9 through 12 in San Diego, California.

During clinical trials, individuals treated with iptacopan had increased hemoglobin levels and did not need to receive blood transfusions.

Currently, there is no established standard of care treatment approach of HGBL, with frontline interventions consisting of chemo-immunotherapies.

Pirtobrutinib is the first and only non-covalent BTK inhibitor to be approved by the FDA and is indicated for adult patients who already received at least 2 prior lines of therapy.

This is KRP203’s second Orphan Drug Designation and it is the only S1P receptor modulator being developed as an adjunctive and maintenance treatment for blood cancers.

Belantamab mafodotin (Blenrep; GlaxoSmithKline) demonstrated that, when combined with bortezomib and dexamethasone (BorDex), the time to disease progression or death was extended.